You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR Mutations

Showing 1 - 25 of 4,188
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Singapore (Afatinib 40 MG)

Not yet recruiting
  • NSCLC
  • Afatinib 40 MG
  • Singapore, Singapore
    National University Hospital
Sep 25, 2023

NSCLC Trial in Guangzhou (Neratinib tablets)

Not yet recruiting
  • NSCLC
  • Neratinib tablets
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 1, 2023

Lung Cancer Trial in Boston, Nashville

Active, not recruiting
  • Lung Cancer
    • Boston, Massachusetts
    • +1 more
    Dec 28, 2022

    NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • MK-2870
    • +2 more
    • (no location specified)
    Oct 3, 2023

    NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)

    Recruiting
    • Non-small Cell Lung Cancer
    • SH-1028 tablets
    • Placebo SH-1028 tablets
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Oct 6, 2023

    NSCLC Trial in China (BBP-398, osimertinib)

    Recruiting
    • NSCLC
    • Beijing, Beijing, China
    • +4 more
    Sep 4, 2023

    NSCLC Trial in Tai'an (Ametinib combined with bevacizumab)

    Recruiting
    • Non-small Cell Lung Cancer
    • Ametinib combined with bevacizumab
    • Tai'an, Shandong, China
      The Second Affiliated Hospital of Shandong First Medical Univers
    Feb 22, 2023

    NSCLC Trial (Lazertinib group)

    Not yet recruiting
    • NSCLC
    • Lazertinib group
    • (no location specified)
    Jul 14, 2022

    Non Small Cell Lung Cancer Trial in Beijing (DZD9008)

    Recruiting
    • Non Small Cell Lung Cancer
    • Beijing, Beijing, China
      Department of Respiratory and Critical Care Medicine, Peking Uni
    Sep 24, 2022

    NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
    Jul 9, 2023

    Osimertinib for NSCLC With Uncommon EGFR Mutations

    Enrolling by invitation
    • Carcinoma, Non-Small-Cell Lung
    • Genes, erbB-1
    • Ramat Gan, Israel
      Sheba Medical Centre
    Jun 14, 2022

    Furmonertinib, EGFR-mutation, NSCLC Trial in Beijing (Furmonertinib)

    Recruiting
    • Furmonertinib
    • +3 more
    • Beijing, China
      Ethics Committee
    Jul 15, 2022

    NSCLC Trial (Sutetinib Maleate Capsule)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Sutetinib Maleate Capsule
    • (no location specified)
    Aug 18, 2023

    Non Small Cell Lung Cancer Trial in Mexico City (Metformin Hydrochloride, Placebo)

    Recruiting
    • Non Small Cell Lung Cancer
    • Metformin Hydrochloride
    • Placebo
    • Mexico City, Mexico
      Instituto Nacional de Cancerologia
    Jul 21, 2022

    NSCLC Trial in Seoul (Lazertinib)

    Not yet recruiting
    • NSCLC
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Mar 11, 2022

    NSCLC Trial (TAS3351 oral administration)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • TAS3351 oral administration
    • (no location specified)
    Mar 8, 2023

    Non Small Cell Lung Cancer Trial in Durham, Columbus, Pittsburgh (osimertinib)

    Active, not recruiting
    • Non Small Cell Lung Cancer
    • Durham, North Carolina
    • +2 more
    Jun 30, 2022

    NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Fairfax, Virginia
      NEXT Virginia
    Sep 18, 2023

    Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19 Trial in France (Plasma ctDNA, FFPE blocks)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +3 more
    • Plasma ctDNA
    • FFPE blocks
    • Angers, France
    • +35 more
    Sep 19, 2023

    Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation Trial in Japan (Pembrolizumab, Lenvatinib, Carboplatin)

    Recruiting
    • Non-squamous Non-small-cell Lung Cancer
    • EGFR Activating Mutation
    • Urayasu, Chiba, Japan
    • +9 more
    Jul 19, 2022

    EGFR Gene Mutation, Nonsmall Cell Lung Cancer Trial in Washington, Hackensack (Dasatinib, Osimertinib)

    Active, not recruiting
    • EGFR Gene Mutation
    • Nonsmall Cell Lung Cancer
    • Washington, District of Columbia
    • +1 more
    Jan 9, 2022

    Bronchial Tumors Trial in Germany, Spain (EGF816, Trametinib)

    Recruiting
    • Bronchial Neoplasms
    • Cologne, Germany
    • +6 more
    Nov 2, 2022

    Lung Cancer, EGFR Gene Mutation, EGFR Trial in Charlottesville (Sensus Smartwatch Application, RX Cap, Fitbit Sense)

    Recruiting
    • Lung Cancer
    • +3 more
    • Sensus Smartwatch Application
    • +3 more
    • Charlottesville, Virginia
      University of Virginia
    Aug 26, 2022

    NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +

    Recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Befotertinib + Icotinib placebo
    • Icotinib + Befotertinib placebo
    • Beijing, China
    • +2 more
    Sep 20, 2023

    Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer Trial in Puerto Rico, United States (HBI-2376)

    Recruiting
    • Non Small Cell Lung Cancer
    • +6 more
    • Duarte, California
    • +11 more
    Aug 23, 2022